A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3183 participants.

Also called NCT02692716

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,183 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02692716
  • EudraCT 2015-003563-10
Other papers using this trial's data
  • Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England journal of medicine, 2019-08-29 DOI, PubMed 31185157

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Argentina, Brazil, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02692716. Randomized; double masking; primary purpose treatment. Start 2017-01-17 (actual); primary completion 2018-09-25 (actual). Results posted on 2020-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Acronym
PIONEER 6
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02692716
Content hash
c00b8694ef310a5c6f37b964bc416a7105bc892144f29e1a0d7ad4db333a6ae6